All In MedTech

Device Trial Radar · NCT06989775

BoxX-NoAF Clinical Trial

EnCompass Clamp and the AtriClip in Box Lesion and Left Atrial Appendage EXclusion Procedure for the Prevention of New Onset of Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 960 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

960

Planned (sponsor's estimate)

Start

Oct 24, 2025

Primary completion

Feb 2027

Study completion Dec 2029

Sponsor

Lead sponsor
AtriCure, Inc.Public (ATRC)
Sponsor type
Industry
First posted
May 25, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial to evaluate if prophylactic ablation and exclusion of the Left Atrial Appendage at the time of other routine cardiac surgery can reduce the incidence of post operative AF and clinical AF during long term follow up in patients who have not yet developed AF but are at risk.

Conditions

  • Post Operative Atrial Fibrillation
  • Atrial Fibrillation, Postoperative

Interventions

  • Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion SystemDevice

    Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness EndpointTime frame: 30 days post index cardiac surgical procedure
  2. Primary Safety EndpointTime frame: 30 days post index cardiac surgical procedure

Locations

37 sites in 2 countries. Site status is shown where the registry gives one.

  • Honor Health

    Scottsdale, Arizona · Recruiting

  • St. Bernards Medical Center

    Jonesboro, Arkansas · Recruiting

  • Sharp Memorial Hospital

    San Diego, California · Recruiting

34 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.